BRIEF published on 11/05/2025 at 13:51, 11 months 25 days ago Croissance continue pour Medincell et nouvelles perspectives avec l'Olanzapine LAI Schizophrénie Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 11 months 25 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
PRESS RELEASE published on 11/05/2025 at 13:46, 11 months 25 days ago Informations privilégiées / Autres communiqués Medincell annonce la poursuite de la croissance d'UZEDY® et la préparation du dépôt de l'Olanzapine LAI sur le marché américain par Teva Pharmaceuticals Croissance Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
BRIEF published on 10/10/2025 at 22:16, 1 year ago La FDA approuve UZEDY pour le traitement du trouble bipolaire de type I chez l'adulte Approbation De La FDA Traitement De Santé Mentale UZEDY Trouble Bipolaire I Risperidone
BRIEF published on 10/10/2025 at 22:16, 1 year ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 1 year ago Informations privilégiées / Autres communiqués La FDA approuve l’extension d’indication de UZEDY® pour le traitement de patients atteints de trouble bipolaire de type I par Teva Pharmaceuticals et Medincell FDA Medincell Teva Pharmaceuticals UZEDY Traitement Bipolaire
PRESS RELEASE published on 10/10/2025 at 22:11, 1 year ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 1 year 1 month ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
BRIEF published on 09/17/2025 at 14:05, 1 year 1 month ago Medincell et Teva présentent les données de phase 3 sur l'olanzapine LAI Essai De Phase 3 Traitement De La Schizophrénie Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/17/2025 at 14:00, 1 year 1 month ago Inside Information / Other news releases Medincell and Teva to discuss Phase 3 Olanzapine LAI data from SOLARIS Trial at 2025 Psych Congress. Webcast details available on Teva's IR website Phase 3 Medincell Teva SOLARIS Trial Olanzapine LAI
Published on 10/30/2026 at 23:35, 3 hours 58 minutes ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 4 hours 3 minutes ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 6 hours 46 minutes ago CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 8 hours 33 minutes ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 12 hours 3 minutes ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/30/2026 at 22:49, 4 hours 44 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 8 hours 55 minutes ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 4 hours 33 minutes ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 4 hours 33 minutes ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
